Healthcare >> CEO Interviews >> June 1, 2009
THOMAS A. MOORE was named Advaxis, Inc.'s Chairman and Chief Executive Officer on December 15, 2006. He is currently also Director at Alteon, Inc., a publicly traded developer of pharmaceuticals for the treatment of diabetes and age-related diseases; El Dorado Inc., a targeted marketer to unassimilated Hispanics; Medmeme, which measures medical education effectiveness; MD Offices, an Electronic Medical Records provider; and Opt-e-scrip, Inc., which markets a clinical system to compare multiple drugs in the same patient. He also serves as Chairman of the board of directors of Mayan Pigments, Inc., which has developed and patented Mayan pigment technology. Previously, from June 2002 to June 2004, Mr. Moore was President and Chief Executive Officer of Biopure Corporation, a developer of oxygen therapeutics that are intravenously administered to deliver oxygen to the body's tissues. From 1996 to November 2000, he was President and Chief Executive Officer of Nelson Communications. Previously, Mr. Moore had a 23-year career with the Procter & Gamble Company in multiple managerial positions, including President of Health Care Products, where he was responsible for prescription and over-the-counter medications worldwide, and where he served as Group Vice President of the Procter & Gamble Company. Profile
revenues and number of employees?
Mr. Moore: Our market cap is about $16 million. We have nine employees. Our
